FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:04:046 | Achieving Early Clinical Response was Associated with Cumulative Benefits on Disease Impact up to 2 Years in Patients with Active Psoriatic Arthritis Treated with Bimekizumab William Tillett1|2, Joseph F Merola3, Iain B Mcinnes4, Kenneth B Gordon5, Richard B Warren6, Patrick Healy7, Jérémy Lambert8, Heather Edens9, Barbara Ink10, Paola Volpe11, Laure Gossec12 | 1Royal National Hospital of Rheumatic Diseases Bath, United Kingdom; 2Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath Bath, United Kingdom; 3Department of Dermatology and Department of Medicine, Division of Rheumatology, Utah Southwestern Medical Center Dallas, USA; 4College of Medical Veterinary and Life Sciences, University of Glasgow Glasgow, United Kingdom; 5Department of Dermatology, Medical College of Wisconsin Milwaukee, USA; 6Northern Care Alliance, NHS Foundation Trust and Manchester Academic Health Science Centre, University of Manchester Manchester, United Kingdom; 7UCB Morrisville, USA; 8UCB Colombes, France; 9UCB Smyrna, USA; 10UCB Slough, United Kingdom; 11UOC Reumatologia, P.O. Spirito Santo Pescara, Italy; 12Sorbonne Universite and Pitie-Salpetriere Hospital Paris, France
37 -
PO:02:025 | Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors Valentina Carlini1, Philip Mease2, William Tillett3, Xiaolan Ye4, Christopher Saffore4, Molly Edwards5, Isabel Truman5, Sophie Barlow5, Jayne Stigler4, Bhumik Parikh4, Daniel Aletaha6 | 1Abbvie srl Roma, Italy; 2University of Washington School of Medicine Seattle, United States Minor Outlying Islands; 3Department of Rheumatology, Royal National Hospital for Rheumatic Diseases Bath, United Kingdom; 4Abbvie Inc. North Chicago, United States Minor Outlying Islands; 5Adelphi Real World Bollington, United Kingdom; 6Division of Rheumatology, Department of Medicine, Medical University of Vienna, Vienna, Austria
26 -
PO:20:006 | Efficacy of denosumab in glucocorticoid-induced osteoporosis patients with prior exposure to intravenous aminobisphosphonates Kiren Khalid1, Alessandro Giollo1, Mariangela Salvato1, Francesca Frizzera1, Lorenzo Di Luozzo1, Bernd Raffeiner2, Andrea Doria1 | 1Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy; 2Department of Rheumatology, Bolzano Central Hospital, Bolzano, Italy
27 -
PO:02:021 | Sustained Improvements with Bimekizumab in Pain, Morning Stiffness, Fatigue, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies Victoria Navarro-Compán1, Uta Kiltz2|3, Philip J Mease4, Maureen Dubreuil5, Karl Gaffney6, Atul Deodhar7, Christine De La Loge8, Diana Voiniciuc9, Jason Coarse10, Ilaria Spadafora11, Helena Marzo-Ortega12 | 1La Paz University Hospital, IdiPaz, Department of Rheumatology Madrid Spain; 2Ruhr-University Bochum Bochum Germany; 3Rheumazentrum Ruhrgebiet Herne, Germany; 4Department of Rheumatology, Swedish Medical Center and Providence St. Joseph Health and University of Washington Seattle, USA; 5Boston University School of Medicine, Department of Rheumatology Boston, USA; 6Norfolk and Norwich University Hospital NHS Trust, Department of Rheumatology Norfolk, United Kingdom; 7Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases Portland, USA; 8UCB Brussels, Belgium; 9UCB Slough, United Kingdom; 10UCB Morrisville, USA; 11UCB Milan, Italy; 12NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom
26 -
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
51 -
PO:03:034 | Inhibition of Radiographic Progression with Bimekizumab Treatment Observed in bDMARD-Naïve Patients with Active Psoriatic Arthritis at 2 Years: Results from a Phase 3 Study and its Open-Label Extension Laura C Coates1, M Elaine Husni2, Mitsumasa Kishimoto3, Proton Rahman4, Philipp Sewerin5, Enrique R Soriano6, Barbara Ink7, Rajan Bajracharya7, Jason Coarse8, Philip J Mease9, Emanuela Mazzola10, Peter Nash11 | 1NDORMS, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust Oxford, United Kingdom; 2Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Cleveland, USA; 3Department of Nephrology and Rheumatology, Kyorin University School of Medicine Tokyo, Japan; 4Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Memorial University of Newfoundland St. Johns, Canada; 5Rheumazentrum Ruhrgebiet, University Hospital of the Ruhr University Bochum Herne Germany; 6Hospital Italiano de Buenos Aires and University Institute Hospital Italiano de Buenos Aires Buenos Aires, Argentina; 7UCB Slough, United Kingdom; 8UCB Morrisville, USA; 9Department of Rheumatology, Providence-Swedish Medical Center and University of Washington Seattle, USA; 10UCB Milan, Italy; 11School of Medicine, Griffith University, Brisbane, Australia
53 -
PO:01:006 | Increased risk of cancer recurrence or mortality associated with DMARDs? Laura Scagnellato1, Giacomo Cozzi1, Mariagrazia Lorenzin1, Mariangela Salvato1, Alessandro Giollo1, Bernd Raffeiner1, Antonia Calligaro1, Teresa Del Ross1, Sara Bindoli1, Margherita Zen1, Paolo Sfriso1, Andrea Doria1, Roberta Ramonda1. | 1UOC Reumatologia, Dipartimento di Medicina dei Sistemi DIMED, Ospedale Università di Padova, Padova, Italy.
173 -
PO:01:007 | Modulation of cellular senescence in psoriatic arthritis: exploring the potential impact of b/tsDMARDs treatment on telomere length, mtDNA copy number, and oxidative damage Eneida Cela1, Giada De Benedittis2, Arianna D'Antonio1, Andrea Latini3, Chiara Morgante2, Cinzia Cicacci3, Paola Conigliaro1, Mauro Fatica1, Giulia Mori1, Giuseppe Novelli2, Paola Borgiani2, Maria Sole Chimenti1. | 1Rheumatology, Allergology and Clinical Immunology, Department of System Medicine, University of Rome Tor Vergata, Rome, Italy; 2Department of Biomedicine and Prevention, Section of Genetics, University of Rome Tor Vergata, Rome, Italy; 3UniCamillus Saint Camillus International University of Health Sciences, Rome, Italy.
171
